START and Advarra Unite to Streamline Early-Phase Oncology Trials with Speed and Precision

The START Center for Cancer Research has announced a strategic partnership with Advarra to accelerate and streamline early-phase oncology trials across its global network. By integrating Advarra’s regulatory expertise and advanced technology solutions, including a CTMS and eReg platform, the collaboration aims to build a more connected, efficient, and patient-centric research ecosystem. START has conducted over 1,000 trials and supported 45 FDA/EMA approvals, reinforcing its leadership in advancing cancer therapies.

Through this strategic alliance, START’s global site network will leverage Advarra’s comprehensive portfolio of products and services. Advarra will be START’s preferred provider for Independent Review Board (IRB) and Institutional Biosafety Committee (IBC) services. Additionally, START will leverage new technologies that seamlessly integrate with Advarra’s OnCore Clinical Trial Management System (CTMS), which supports over 85% of NCI-designated cancer centers and has been actively used to improve operational efficiency across START’s network since 2024.

“Oncology drug development companies are under intense pressure to deliver innovative treatments to patients swiftly and reliably,” said Nick Slack, MBE, Chairman and CEO of START. “By partnering with Advarra, we are building a truly interconnected ecosystem, leveraging the best technology and regulatory expertise in the industry, and adopting Advarra’s standardized workflows and integrated platforms will significantly enhance our operational efficiency, compliance, and quality—ensuring that we not only accelerate the delivery of breakthrough therapies to patients but also uphold the highest standards of patient safety. We’re proud to advance our mission with a partner equally committed to excellence.”

The partnership represents a substantial investment in clinical trial infrastructure, one that is already bearing fruit. OnCore and Advarra’s regulatory services are currently in use across START’s global network, with full deployment of eReg underway. This integrated approach will standardize trial workflows, reduce administrative burdens, and enhance site-level coordination—ultimately enabling faster startup and execution of trials for patients in both academic and community settings.

Gadi Saarony, CEO of Advarra, emphasized the alignment of missions between the two organizations. “With deep expertise in oncology research, decades-long partnerships with leading cancer centers, and a proven track record of delivering solutions for regulatory compliance and operational excellence, our role is to help remove barriers to research—streamlining the path from discovery to care. We’re proud to partner with START as it expands its reach and impact around the world.”

START’s network includes ten clinical trial sites spanning North America, and Europe, with over 1,000 early-phase studies conducted and 45 therapies brought to market through FDA or EMA approvals. By adopting Advarra’s streamlined platforms and processes, START is positioning itself as a model for scalable, high-quality oncology research conducted in real-world settings.

For health professionals and trial sponsors alike, this alliance signals a new era of operational efficiency and research agility—one that could significantly shorten the timeline from discovery to delivery in the fight against cancer.